Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
तुलना करने के लिए मीट्रिक्स | ERAS | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधERASपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −34.0x | −4.2x | −0.5x | |
PEG अनुपात | −0.93 | −0.15 | 0.00 | |
क़ीमत/बुक | 13.0x | 3.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 8.2x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 43.2% | 69.4% | 52.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 10.5% | 7.8% | अनलॉक करें |